Univest
Univest
  • Markets

Riddhi Siddhi Gluco Biols Q4 FY26 Results: Loss Rs 33 Cr

  • May 26, 2026
  • Posted by: Kunal Singla
  • Category: News
No Comments
Riddhi Siddhi Gluco Biols

Riddhi Siddhi Gluco Biols Q4 FY26 results were declared on May 25, 2026. The company reported net loss of Rs 33 crore for the quarter ended March 31, 2026, down 760.0% YoY compared to Rs 5 crore in Q4 FY25. Revenue from operations was Rs 9 crore, down 67.9% YoY. Results are on a Consolidated basis. Riddhi Siddhi Gluco Biols is a Starch and Biochemicals company listed on Indian stock exchanges.

Click Here – Get Free Investment Predictions

Table of Contents

Toggle
  • Riddhi Siddhi Gluco Biols Q4 FY26 Financial Highlights
  • Riddhi Siddhi Gluco Biols Q4 FY26 Performance Analysis
  • Key Factors Driving Riddhi Siddhi Gluco Biols Q4 FY26 Results
    • Revenue and Business Execution
    • Profitability and Margin Trends
    • India Macro Environment Q4 FY26
    • FY27 Outlook
  • Frequently Asked Questions on the company
    • What is Riddhi Siddhi Gluco Biols Q4 FY26 net profit?
    • What is Riddhi Siddhi Gluco Biols Q4 FY26 revenue?
    • When were Riddhi Siddhi Gluco Biols Q4 FY26 results declared?
    • Is Riddhi Siddhi Gluco Biols a good investment after Q4 FY26?

Riddhi Siddhi Gluco Biols Q4 FY26 Financial Highlights

Metric Q4 FY26 (Rs Cr) Q4 FY25 (Rs Cr) YoY Change
Revenue Rs 9 crore Rs 28 crore -67.9%
Net Loss 33 5 -760.0%
Basis Consolidated

Note: Riddhi Siddhi Gluco Biols Q4 FY26 results declared May 25, 2026. Data sourced from Screener.in BSE filings. Verify from audited statements before investment decisions.

Riddhi Siddhi Gluco Biols Q4 FY26 Performance Analysis

The Riddhi Siddhi Gluco Biols Q4 FY26 results reflect the company’s financial performance during the January to March 2026 quarter. The quarter shows near-term profitability challenges requiring management focus in FY27. Riddhi Siddhi Gluco Biols operates in the Starch and Biochemicals sector, which benefits from India’s GDP growth above 6.5% in FY26.

Revenue of Rs 9 crore was down 67.9% YoY. Revenue moderation reflects near-term demand headwinds.

Screen the best stocks on the Univest Screener.

Key Factors Driving Riddhi Siddhi Gluco Biols Q4 FY26 Results

Revenue and Business Execution

Revenue of Rs 9 crore in Riddhi Siddhi Gluco Biols Q4 FY26 was down 67.9% YoY. Revenue pressure reflects near-term demand headwinds in the Starch and Biochemicals market. The January to March quarter is the fiscal year-end period characterised by strong order execution and year-end activity across Indian companies.

Profitability and Margin Trends

The Riddhi Siddhi Gluco Biols Q4 FY26 net loss of Rs 33 crore down 760.0% YoY. Net loss reflects ongoing operational challenges with FY27 recovery as management’s focus.

India Macro Environment Q4 FY26

India’s macroeconomic environment in Q4 FY26 was supportive with GDP growth above 6.5%, government capex of Rs 11.21 lakh crore budgeted for FY27, and resilient domestic consumption. The Reserve Bank of India’s accommodative stance supported credit conditions. The Starch and Biochemicals sector benefited from these structural tailwinds during the January to March 2026 quarter.

FY27 Outlook

Following the firm results, management guidance on FY27 revenue growth, margin improvement roadmap, and capital allocation priorities will be key investor watchpoints. The Starch and Biochemicals sector continues to benefit from India’s long-term structural growth story including urbanisation, infrastructure investment, and rising domestic consumption. Returning to profitability through operational improvements will define the FY27 strategy.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.

Frequently Asked Questions on the company

What is Riddhi Siddhi Gluco Biols Q4 FY26 net profit?

Ans. Riddhi Siddhi Gluco Biols Q4 FY26 reported net loss of Rs 33 crore, down 760.0% YoY from Rs 5 crore in Q4 FY25. Verify from BSE/NSE audited filings.

What is Riddhi Siddhi Gluco Biols Q4 FY26 revenue?

Ans. Riddhi Siddhi Gluco Biols Q4 FY26 revenue was Rs 9 crore, down 67.9% YoY. Verify from BSE/NSE filings.

When were Riddhi Siddhi Gluco Biols Q4 FY26 results declared?

Ans. Riddhi Siddhi Gluco Biols Q4 FY26 results were declared on May 25, 2026, at the board of directors meeting approving audited Q4 and full-year FY26 financial statements.

Is Riddhi Siddhi Gluco Biols a good investment after Q4 FY26?

Ans. Investment decisions require individual assessment of fundamentals, valuation, and risk tolerance. This article is educational only. Consult a SEBI-registered financial advisor before investing.

Investments in securities are subject to market risk. This content is for educational purposes only. Verify all figures from BSE/NSE filings. Consult a SEBI-registered financial advisor.



News Q4 Results
Author: Kunal Singla
Kunal Singla is the Associate Director - Research at Univest, leading quantitative equity research, intraday trading setups, and derivatives strategy. With 4+ years of experience in Indian equity markets, he combines rigorous quantitative methods with classical technical analysis to build high-conviction research frameworks for retail and advisory clients. He holds an MSc from the Indian Institute of Technology (IIT) Delhi — one of India's most selective institutions — and has completed the Certificate in Quantitative Finance (CQF), a globally recognised programme covering derivatives pricing, risk modelling, machine learning for finance, and advanced portfolio theory. This combination places him in a small group of Indian analysts with both deep academic training in quantitative methods and SEBI-recognised research credentials. Kunal holds seven SEBI-recognised NISM certifications spanning research, derivatives, portfolio management, and securities operations: Series-XV (Research Analyst), Series-XXI-A (Portfolio Managers), Series-XVI (Commodity Derivatives), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-V-A (Mutual Fund Distributors), and Series-I (Currency Derivatives). At Univest — India's SEBI-registered research and advisory platform — Kunal leads research inputs for Pro Lite, Pro Super, Pro Gold, and Pro Commodity advisory services, alongside publishing intraday stock picks on Univest Blogs.

Leave a Reply Cancel reply